tadalafil has been researched along with medroxyprogesterone acetate in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (medroxyprogesterone acetate) | Trials (medroxyprogesterone acetate) | Recent Studies (post-2010) (medroxyprogesterone acetate) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 5,123 | 1,115 | 1,099 |
| Protein | Taxonomy | tadalafil (IC50) | medroxyprogesterone acetate (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.924 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.013 | |
| Progesterone receptor | Homo sapiens (human) | 2.5081 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.019 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 1.197 | |
| Androgen receptor | Homo sapiens (human) | 0.0061 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.279 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.019 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.197 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 1.4059 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 4.0405 | |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | 1.8 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.924 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for tadalafil and medroxyprogesterone acetate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |